Spinal fluid injection trial offers hope for rare nerve disease
NCT ID NCT06620809
Summary
This early-stage trial is testing whether tiny particles derived from human neural stem cells, called NouvSoma001, can help control neuromyelitis optica spectrum disorders (NMOSD). The study will first find a safe dose by giving the treatment via spinal tap to small groups, then expand to 60 participants to compare the treatment against a placebo. Researchers will monitor safety and look for improvements in pain, disability, vision, and quality of life over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.